LY294002 potentiates the anti-cancer effect of oxaliplatin for gastric cancer via death receptor pathway

World Journal of Gastroenterology

Volumn 17, Issue 2, 2011, Pages 181-190

  Liu, Jie ^a   Fu, Xue Qiong ^a   Zhou, Wei ^a   Yu, Hong Gang ^b   Yu, Jie Ping ^b   Luo, He Sheng ^b  

^a WUHAN UNIVERSITY   (China)

^b RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Apoptosis; Death receptor pathway; Gastric cancer; Ly294002; Oxaliplatin; Phosphatidylino sitol 3' kinase akt pathway

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CASPASE 3; CASPASE 8; DEATH RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OXALIPLATIN; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B;

ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL ACTIVATION; CELL DEATH; CELL VIABILITY; FLOW CYTOMETRY; GEL MOBILITY SHIFT ASSAY; GROWTH INHIBITION; IMMUNOPRECIPITATION; IN VITRO STUDY; MALE; MOUSE; NICK END LABELING; NONHUMAN; PROTEIN EXPRESSION; STOMACH CANCER; TUMOR GROWTH; WESTERN BLOTTING;

EID: 79955754131     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v17.i2.181     Document Type: Article

References (45)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108
2. Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease, and the different disease hypothesis. Cancer 2000; 88: 921-932
3. Sasako M, Inoue M, Lin JT, Khor C, Yang HK, Ohtsu A. Gastric Cancer Working Group report. Jpn J Clin Oncol 2010; 40 Suppl 1: i28-i37
4. Boudný V, Vrána O, Gaucheron F, Kleinwachter V, Leng M, Brabec V. Biophysical analysis of DNA modified by 1,2-di-aminocyclohexane platinum(II) complexes. Nucleic Acids Res 1992; 20: 267-272
5. Kollmannsberger C, Quietzsch D, Haag C, Lingenfelser T, Schroeder M, Hartmann JT, Baronius W, Hempel V, Clemens M, Kanz L, Bokemeyer C. A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. Br J Cancer 2000; 83: 458-462
6. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358: 36-46
7. Oki E, Baba H, Tokunaga E, Nakamura T, Ueda N, Futatsugi M, Mashino K, Yamamoto M, Ikebe M, Kakeji Y, Maehara Y. Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer. Int J Cancer 2005; 117: 376-380
8. Yang X, Fraser M, Moll UM, Basak A, Tsang BK. Akt-medi-ated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway. Cancer Res 2006; 66: 3126-3136
9. Burk DT, Bender DJ. Use and perceived effectiveness of student support services in a frst-year dental student population. J Dent Educ 2005; 69: 1148-1160
10. Stassi G, Garofalo M, Zerilli M, Ricci-Vitiani L, Zanca C, To-daro M, Aragona F, Limite G, Petrella G, Condorelli G. PED mediates AKT-dependent chemoresistance in human breast cancer cells. Cancer Res 2005; 65: 6668-6675
11. Ang KL, Shi DL, Keong WW, Epstein RJ. Upregulated Akt signaling adjacent to gastric cancers: implications for screening and chemoprevention. Cancer Lett 2005; 225: 53-59
12. Vega F, Medeiros LJ, Leventaki V, Atwell C, Cho-Vega JH, Tian L, Claret FX, Rassidakis GZ. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplas-tic large cell lymphoma. Cancer Res 2006; 66: 6589-6597
13. Garcia GE, Nicole A, Bhaskaran S, Gupta A, Kyprianou N, Kumar AP. Akt-and CREB-mediated prostate cancer cell proliferation inhibition by Nexrutine, a Phellodendron amurense extract. Neoplasia 2006; 8: 523-533
14. Zhang HM, Rao JN, Guo X, Liu L, Zou T, Turner DJ, Wang JY. Akt kinase activation blocks apoptosis in intestinal epithelial cells by inhibiting caspase-3 after polyamine depletion. J Biol Chem 2004; 279: 22539-22547
15. Vanden Berghe W, De Bosscher K, Boone E, Plaisance S, Haegeman G. The nuclear factor-kappaB engages CBP/p300 and histone acetyltransferase activity for transcriptional activation of the interleukin-6 gene promoter. J Biol Chem 1999; 274: 32091-32098
16. Chen Y, Wang Z, Chang P, Xiang L, Pan F, Li J, Jiang J, Zou L, Yang L, Bian Z, Liang H. The effect of focal adhesion kinase gene silencing on 5-fuorouracil chemosensitivity involves an Akt/NF-kappaB signaling pathway in colorectal carcinomas. Int J Cancer 2010; 127: 195-206
17. Almeida GM, Duarte TL, Steward WP, Jones GD. Detection of oxaliplatin-induced DNA crosslinks in vitro and in cancer patients using the alkaline comet assay. DNA Repair (Amst) 2006; 5: 219-225
18. Scheeff ED, Briggs JM, Howell SB. Molecular modeling of the intrastrand guanine-guanine DNA adducts produced bycisplatin and oxaliplatin. Mol Pharmacol 1999; 56: 633-643
19. Legallicier B, Leclere C, Monteil C, Elkaz V, Morin JP, Fil-lastre JP. The cellular toxicity of two antitumoural agents derived from platinum, cisplatinum versus oxaliplatinum, on cultures of tubular proximal cells. Drugs Exp Clin Res 1996; 22: 41-50
20. Christian MC. The current status of new platinum analogs. Semin Oncol 1992; 19: 720-733
21. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006; 24: 2903-2909
22. Hartmann W, Küchler J, Koch A, Friedrichs N, Waha A, Endl E, Czerwitzki J, Metzger D, Steiner S, Wurst P, Leuschner I, von Schweinitz D, Buettner R, Pietsch T. Activation of phosphatidylinositol-3'-kinase/AKT signaling is essential in hepatoblastoma survival. Clin Cancer Res 2009; 15: 4538-4545
23. Gao N, Flynn DC, Zhang Z, Zhong XS, Walker V, Liu KJ, Shi X, Jiang BH. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells. Am J Physiol Cell Physiol 2004; 287: C281-C291
24. Krystal GW, Sulanke G, Litz J. Inhibition of phosphatidylino-sitol 3-kinase-Akt signaling blocks growth, promotes apopto-sis, and enhances sensitivity of small cell lung cancer cells to chemotherapy. Mol Cancer Ther 2002; 1: 913-922
25. Su JD, Mayo LD, Donner DB, Durden DL. PTEN and phos-phatidylinositol 3'-kinase inhibitors up-regulate p53 and block tumor-induced angiogenesis: evidence for an effect on the tumor and endothelial compartment. Cancer Res 2003; 63: 3585-3592
26. Polo ML, Arnoni MV, Riggio M, Wargon V, Lanari C, No-varo V. Responsiveness to PI3K and MEK inhibitors in breast cancer. Use of a 3D culture system to study pathways related to hormone independence in mice. PLoS One 2010; 5: e10786
27. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997; 91: 479-489
28. Kobayashi I, Semba S, Matsuda Y, Kuroda Y, Yokozaki H. Significance of Akt phosphorylation on tumor growth and vascular endothelial growth factor expression in human gastric carcinoma. Pathobiology 2006; 73: 8-17
29. Shin JY, Kim JO, Lee SK, Chae HS, Kang JH. LY294002 may overcome 5-FU resistance via down-regulation of activated p-AKT in Epstein-Barr virus-positive gastric cancer cells. BMC Cancer 2010; 10: 425
30. Alexia C, Bras M, Fallot G, Vadrot N, Daniel F, Lasfer M, Tamouza H, Groyer A. Pleiotropic effects of PI-3' kinase/Akt signaling in human hepatoma cell proliferation and drug-induced apoptosis. Ann N Y Acad Sci 2006; 1090: 1-17
31. Pencreach E, Guérin E, Nicolet C, Lelong-Rebel I, Voegeli AC, Oudet P, Larsen AK, Gaub MP, Guenot D. Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/ hypoxia-inducible factor-1alpha axis. Clin Cancer Res 2009; 15: 1297-1307
32. Karam AK, Santiskulvong C, Fekete M, Zabih S, Eng C, Dori-go O. Cisplatin and PI3kinase inhibition decrease invasion and migration of human ovarian carcinoma cells and regulate matrix-metalloproteinase expression. Cytoskeleton (Hoboken) 2010; 67: 535-544
33. Leelawat K, Narong S, Udomchaiprasertkul W, Leelawat S, Tungpradubkul S. Inhibition of PI3K increases oxaliplatin sensitivity in cholangiocarcinoma cells. Cancer Cell Int 2009; 9: 3
34. Yu HG, Ai YW, Yu LL, Zhou XD, Liu J, Li JH, Xu XM, Liu S, Chen J, Liu F, Qi YL, Deng Q, Cao J, Liu SQ, Luo HS, Yu JP. Phosphoinositide 3-kinase/Akt pathway plays an importantrole in chemoresistance of gastric cancer cells against etopo-side and doxorubicin induced cell death. Int J Cancer 2008; 122: 433-443
35. Ravi R, Bedi GC, Engstrom LW, Zeng Q, Mookerjee B, Géli-nas C, Fuchs EJ, Bedi A. Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB. Nat Cell Biol 2001; 3: 409-416
36. Wang Y, Cui H, Schroering A, Ding JL, Lane WS, McGill G, Fisher DE, Ding HF. NF-kappa B2 p100 is a pro-apoptotic protein with anti-oncogenic function. Nat Cell Biol 2002; 4: 888-893
37. Kimura M, Haisa M, Uetsuka H, Takaoka M, Ohkawa T, Kawashima R, Yamatsuji T, Gunduz M, Kaneda Y, Tanaka N, Naomoto Y. TNF combined with IFN-alpha accelerates NF-kappaB-mediated apoptosis through enhancement of Fas expression in colon cancer cells. Cell Death Differ 2003; 10: 718-728
38. Thorburn A. Death receptor-induced cell killing. Cell Signal 2004; 16: 139-144
39. Peter ME, Krammer PH. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ 2003; 10: 26-35
40. Thome M, Tschopp J. Regulation of lymphocyte proliferation and death by FLIP. Nat Rev Immunol 2001; 1: 50-58
41. Kim JY, Kim EH, Park SS, Lim JH, Kwon TK, Choi KS. Quer-cetin sensitizes human hepatoma cells to TRAIL-induced apoptosis via Sp1-mediated DR5 up-regulation and protea-some-mediated c-FLIPS down-regulation. J Cell Biochem 2008; 105: 1386-1398
42. Kim DJ, Park C, Oh B, Kim YY. Association of TRAF2 with the short form of cellular FLICE-like inhibitory protein prevents TNFR1-mediated apoptosis. J Mol Signal 2008; 3: 2
43. Bin L, Li X, Xu LG, Shu HB. The short splice form of Casper/ c-FLIP is a major cellular inhibitor of TRAIL-induced apopto-sis. FEBS Lett 2002; 510: 37-40
44. Park SJ, Kim YY, Ju JW, Han BG, Park SI, Park BJ. Alternative splicing variants of c-FLIP transduce the differential signal through the Raf or TRAF2 in TNF-induced cell proliferation. Biochem Biophys Res Commun 2001; 289: 1205-1210
45. Nam SY, Jung GA, Hur GC, Chung HY, Kim WH, Seol DW, Lee BL. Upregulation of FLIP(S) by Akt, a possible inhibition mechanism of TRAIL-induced apoptosis in human gastric cancers. Cancer Sci 2003; 94: 1066-1073